E156 Micro-Paper · Africa Clinical Trials

Landlocked Nation Penalty

Landlocked African nations face compounded research access barriers — no port in...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
Landlocked Nation Penalty by Country Egypt: N/A Algeria: N/A Morocco: N/A Tunisia: N/A Senegal: N/A Ghana: N/A Nigeria: N/A Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: N/A Uganda: 809 Tanzania: N/A Rwanda: 138 South Africa: N/A Uga 809 Eth 302 Rwa 138 8 809
Landlocked Nation Penalty Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.559
Regional Comparison Africa US Europe 0 50000 100000 150000 200000
Enrollment Distribution Africa Reference 5000 10000 15000 20000 25000
Phase Distribution Africa US Europe Phase 1 11 124.4 101.6 Phase 2 20 155.5 171.2 Phase 3 52 402.2 429.8 Phase 4 12 131.0 93.6 429.8 11
No data
Contribution Breakdown 809 Uganda 344 Malawi 307 Zambia 302 Ethiopia 215 Burkina Fa 796 Others
Research Profile Volume Growth Phase3 Complete Diversity
Why It Matters

Landlocked African nations face compounded research access barriers — no port infrastructure for temperature-sensitive biologics, higher import costs for trial supplies, and limited international connectivity for monitoring visits.

In the spatial mapping of African clinical research, does the pattern of landlocked nation penalty reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Moran's I spatial autocorrelation as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Question

In the spatial mapping of African clinical research, does the pattern of landlocked nation penalty reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Moran's I spatial autocorrelation as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.

Interpretation

Temporal analysis showed 17.

Boundary

1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.